Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS

Article Abstract:

Twice-weekly treatment with sulfadiazine, pyrimethamine, and folinic acid may not be as effective as daily treatment for patients with toxoplasmic encephalitis associated with acquired immunodeficiency syndrome (AIDS). Toxoplasmic encephalitis is an inflammation of the brain. Researchers administered either a daily or twice-weekly dose of sulfadiazine, pyrimethamine, and folinic acid to 105 AIDS patients with a previous episode of toxoplasmic encephalitis. Of the 60 AIDS patients receiving the daily dose, only 6% experienced a recurrence of toxoplasmic encephalitis in the first 12 months. Of the 45 AIDS patients receiving the twice-weekly dose, 30% experienced a recurrence of toxoplasmic encephalitis during this time period. Patients given a daily dose survived for an average of 15.2 months. Patients given a twice-weekly dose survived for an average of 11.9 months.

Complications and side effects, AIDS (Disease), Encephalitis, Pyrimethamine

---

A randomized trial of hte discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection

Article Abstract:

HIV patients whose CD4 T cell counts increase to 200 or more as a result of antiretroviral therapy can stop taking drugs to prevent Pneumocystis carinii pneumonia (PCP). In a study of 714 such patients, none of the 300 patients who stopped taking drugs to prevent PCP developed PCP during a one- to two-year follow-up.

Pneumocystis carinii pneumonia

---

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

Article Abstract:

Nevirapine and efavirenz may be more effective AIDS drugs than abacavir, according to a study of 460 HIV patients. These drugs are often used instead of protease inhibitors because protease inhibitors have serious side effects. In this study, abacavir seemed to have fewer side effects than the other two drugs.

Nevirapine, Abacavir

Similar abstracts:

• Abstracts: Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. The use of corticosteroids in Pneumocystis carinii pneumonia
• Abstracts: A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome
• Abstracts: Treatment for cerebral toxoplasmosis protects against Pneumocystis carinii pneumonia in patients with AIDS. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia
• Abstracts: Failure of recommended maternal therapy to prevent congenital syphilis. Comparison of maternal and newborn serologic tests for syphilis
• Abstracts: Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.